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Background: In rectal cancer therapy, radiotherapy or chemoradiotherapy (RT/CRT) is
extensively used pre-operatively to (i) decrease local recurrence risks, (ii) allow radical
surgery in non-resectable tumors, and (iii) increase the chances of sphincter-saving surgery
or (iv) organ-preservation.There is a growing interest among clinicians and scientists to pro-
long the interval from the RT/CRT to surgery to achieve maximal tumor regression and to
diminish complications during surgery.
Methods: The pros and cons of delaying surgery depending upon the aim of the
pre-operative RT/CRT are critically evaluated.
Results: Depending upon the clinical situation, the need for a time interval prior to surgery
to allow tumor regression varies. In the first and most common situation (i), no regression is
needed and any delay beyond what is needed for the acute radiation reaction in surrounding
tissues to wash out can potentially only be deleterious. After short-course RT (5Gyx5) with
immediate surgery, the ideal time between the last radiation fraction is 2–5 days, since a
slightly longer interval appears to increase surgical complications. A delay beyond 4 weeks
appears safe; it results in tumor regression including pathologic complete responses, but is
not yet fully evaluated concerning oncologic outcome. Surgical complications do not appear
to be influenced by the CRT-surgery interval within reasonable limits (about 4–12 weeks),
but this has not been sufficiently explored. Maximum tumor regression may not be seen
in rectal adenocarcinomas until after several months; thus, a longer than usual delay may
be of benefit in well responding tumors if limited or no surgery is planned, as in (iii) or (iv),
otherwise not.
Conclusion: A longer time interval after CRT is undoubtedly of benefit in some clinical
situations but may be counterproductive in most situations. After short-course RT, long-
term results from the clinical trials are not yet available to routinely recommend an interval
longer than 2–5 days, unless the tumor is non-resectable at diagnosis.
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INTRODUCTION
In rectal cancer, radiotherapy (RT) or chemoradiotherapy (CRT)
is extensively used pre-operatively to decrease the risk of local
failure in resectable tumors by sterilizing microscopic tumor foci
not removed by the surgeon and to allow radical surgery in non-
resectable or difficult to resect tumors. RT/CRT is also used to
increase the chances of sphincter-saving surgery and to omit or
limit the extent of surgery. For a successful outcome, the size or the
stage of the rectal tumor must be decreased in the three last men-
tioned clinical situations, but not in the one mentioned first where
it is sufficient to influence eventual cells remaining after surgery so
that they are no longer clonogenic. An interval between the end of
the RT/CRT is required if tumor regression is required. During the
interval, the acute tissue reaction from the radiation, potentially
increasing the risk of surgical complications, also subsides.
Radiotherapy was early developed in squamous cell carcinomas
from the head and neck region for the same reasons as used in rec-
tal cancer, visually to decrease the risk of loco-regional failure, to
allow surgery, and to preserve the organ function. The RT resulted
in an acute tissue reaction that healed in a couple of weeks, delaying
surgery for about a month. Squamous cell carcinomas regress quite
rapidly. In contrast, when RT was used for adenocarcinomas, like
rectal cancer, it was at an early stage observed that tumor regres-
sion was much slower and did not become maximal until after
several months (Figure 1) (1, 2). A median tumor volume-halving
time of 14 days has later been reported (3).
When RT was applied pre-operatively to rectal cancer it was
usually not required to achieve maximum tumor regression and
the time interval was decided by the acute radiation reaction to
wear off. Thus an interval of 3–5 weeks was chosen. As an alterna-
tive to conventionally fractionated RT, a short-course schedule was
developed for use in resectable tumors. Since there was no need for
tumor regression, surgery was performed immediately, or within
3–5 days from the last radiation fraction (5). If the tumor at surgery
was non-resectable, the abdomen had to be closed. The experi-
ence was then that the tumor regressed and could be resected at
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FIGURE 1 |Time course of complete regression of rectal cancer after
radiation therapy. Above: Results from 22 patients with mobile tumors
treated by radiation alone, 50 Gy in 20 fractions in 4 weeks at PMH, Toronto,
Canada, for whom detailed observations of complete regression were
available (1). The primary tumor was controlled in 21 (38%) of 56 patients with
mobile tumors and in only 6 (9%) of 67 fixed tumors. Below: Results from
1593 patients treated with CRT and selected from the Dutch surgical
colorectal audit (4). The x -axis in the figure above refers to the interval from
the end of RT to surgery (months) and below from start of CRT (weeks). The
number of patients treated with longer intervals is few and these proportions
are thus very uncertain. All data are collected retrospectively and reasons for
the long delay are not known. In spite of this, the figures illustrate that tumor
regression in rectal cancer is slow. Reprinted with permission from Wolters
Kluwer Health (above) and John Wiley and Sons (below).
a later stage. This experience led to the use of the short-course
schedule in elderly or co-morbid patients with non-resectable
tumors, when the reference treatment CRT was not considered
tolerable (6–8).
There is an increasing, clearly articulated view among clinicians
and scientists to prolong the interval to achieve maximal tumor
regression. A complete clinical response (cCR) and, if the patient
is operated upon, a complete pathological response (pCR, i.e.,
ypT0N0) have developed as important prognostic factors indicat-
ing low recurrence risks (9–12). This was known decades ago (2,
13). Recent evidence was subject to a systematic overview includ-
ing 3105 patients with 484 pCRs from 14 studies and reported
improved disease-free survival (DFS) at 5 years (adjusted HR
0.54, 95% CI 0.40–0.73) (14). In another systematic review of
16 studies with 3363 patients (15), a pCR was associated with
fewer local recurrences (odds ratio, OR= 0.25), less distant failures
(OR= 0.23), and improved overall survival (OS) (OR= 3.28) and
DFS (OR= 4.33). pCR is now considered a relevant endpoint after
pre-operative therapy, indicating a prognostically favorable tumor
biological profile with less risk of recurrence and better survival,
although its use as an endpoint in clinical trials has been ques-
tioned (16). Partial regression is likely also relevant (17), although
not universally found (18). The evaluation of pathological tumor
regression is non-standardized and not reproducible (19). Eval-
uations using MRI may be more reproducible and are available
prior to surgery (20). The possibilities to achieve CR are behind
the growing interest in organ-preservation, i.e., to omit surgery or
limit surgery to a local excision (21–24).
The observation of favorable prognosis if cCR/pCR is achieved
has led many investigators to increase the radiation dose to
the tumor center (25, 26), to prolong the interval to surgery,
to add chemotherapy in the interval (27–30), or to start with
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chemotherapy (31–33). All approaches intuitively seem attrac-
tive, and to prolong the interval can be achieved without any
increasing costs. Since there also is an impression that complica-
tions to surgery decrease with longer time intervals, this has been
adopted by many and intervals much longer than the originally
used 3–6 weeks have been applied (3, 14, 34).
This article will critically review in what clinical situations
more down-sizing/down-staging can be beneficial and to review
whether a longer than usual interval in situations where tumor
regression is not of any benefit, actually can be deleterious. The
presentation will include both the time interval after short-course
RT and after conventionally fractionated CRT. The aim was to
include all relevant published literature, but systemic overviews
based primarily only upon retrospective studies are very dif-
ficult to get complete. In the literature searches performed in
August and December 2013, several relevant articles were iden-
tified that was not included in an article claimed to be sys-
tematic and published online during the preparation of this
review (35).
PRE-OPERATIVE RADIOTHERAPY TO IMPROVE LOCAL
CONTROL AND SURVIVAL
In rectal cancer therapy, the pre-treatment division into three
groups, the good–bad–ugly concept (36, 37) has been useful in
the selection of initial therapy, and included in recent guide-
lines/consensus documents (38–41). In early/good tumors, the risk
of local failure is so small, provided proper staging, and surgery
is done, that it is not considered appropriate to reduce it further
with pre-operative RT. There is no consensus on how high the risk
could be, but a risk of at the most 5–8% is reasonable (42). The
patients should participate in this decision, balancing the mor-
bidity from a local failure and the added morbidity to surgery
from the pre-operative RT, but studies on patient preferences in
rectal cancer therapy are few and inconclusive (43–45). In one
study, an absolute 10% difference was required for half of the 50
patients to accept the morbidity from CRT (45). In the intermedi-
ate/bad group, the risk of local failure after surgery alone is higher
or above 8–10%, and the 50–70% reduction from pre-operative
RT/CRT is meaningful. The term intermediate/bad is preferred for
this group, even if most trialists have called these tumors “locally
advanced” (42). In the locally advanced/ugly group, surgery alone
must either be extensive to achieve local radicality (circumferen-
tial resection margin negativity, crm−) or will result in high local
failure rates (≥25%). It is only in this group that tumor regres-
sion is required to achieve high probability of local control after
surgery. The cT3 mrf+ (clinical stage T3 with mesorectal fascia
involvement<1 mm) and most cT4 tumors are considered “ugly.”
In contrast, it is not possible to clearly separate the “good” and
“bad” tumors from each other using T and N stage only since
many other factors like distance form the anus, the size of the
mesorectum (varies according to level, direction, sex, and between
individuals),presence of vascular invasion,and the skill of the mul-
tidisciplinary team are important. The majority of cT1-2 tumors
and many cT3 mrf-tumors in middle and high rectum belong to
the “good” group. Node positivity on MRI is not necessarily suf-
ficient to consider that the risk of local recurrence is sufficiently
high, requiring pre-operative RT/CRT.
The risk of systemic relapse is not identical to the risk of local
relapse, although a strong overlap is seen (36, 46). Node positivity
and extramural vascular invasion are likely more important for
systemic dissemination than local relapse.
TIME INTERVAL AFTER SHORT-COURSE RADIOTHERAPY TO
SURGERY
The “ideal” short-course schedule, five fractions of 5 Gy Mon-
day through Friday with surgery the coming Monday or Tuesday
results in an interval of less than 10 days. Retrospective analyses of
randomized trials have not detected any differences in tumor con-
trol if the RT started on another weekday than Monday, resulting
in a weekend-break during the RT (47, 48). This schedule, devel-
oped to be used in tumors presently designated intermediate/bad
staged by MRI (originally resectable tumors, excluding early, poly-
poid cancers (5) to decrease local failure rates, was not supposed to
result in down-staging (49, 50). A retrospective analysis of Swedish
data showed that down-staging was seen when the interval was
longer than 10 days from the first RT fraction (47). Starting with
anecdotal experiences of patients who had received 5Gyx5 and
where the tumor was found non-resectable at surgery the coming
week but where it could be radically resected several weeks later,
several groups have now reported favorable outcomes after short-
course RT with a delay in elderly and co-morbid patients with
non-resectable rectal cancer not tolerating conventional CRT (6–
8). This has lead to a renewed interest in exploring short-course
RT with a delay also in younger patients with less advanced can-
cers. The Stockholm III trial randomly tested short-course RT with
immediate surgery (reference treatment) against short-course RT
with surgery delayed, initially for 4–6 weeks, but more and more
for 6–8 weeks or long-course RT (2Gyx25) in intermediate rec-
tal cancers. In an interim analysis after inclusion of 303 patients,
all treatment arms were feasible (51). The reference treatment
resulted in more toxicity after surgery than the two other arms,
but this disappeared when patients with a delay from the start of
RT to surgery above 10 days, violating the protocol, were excluded.
Thus, based upon this subgroup analysis, supported by subgroup
analyses of the Stockholm I+ II studies (52) and the TME study
(48, 53), surgery after 5Gyx5 should be performed within 11 days
from the start of RT, or delayed for several weeks in order to min-
imize surgical morbidity and mortality. Even if similar experience
has been reported by others (54, 55), the conclusion is based upon
retrospective studies, and should be interpreted cautiously. In an
analysis of the Stockholm III trial after 657 randomized patients
(585 analyzed) (56) and in a validation set to the Dutch study (48),
the increased toxicity after a slight delay was no longer seen. It can
be speculated that if surgeons know about the risk of increased
toxicity with a slight delay to surgery, it is no longer a risk factor.
Impaired leukocyte response after surgery can be a reason for the
increased risk of toxicity, particularly if surgery is done between
10 to about 21 days after start of RT (52, 55, 56).
In a Polish study, 154 patients with intermediate rectal cancers
were randomized to 5Gyx5 with surgery either 7–10 days or 4–
5 weeks after the end of RT (57). More down-staging was seen, but
the rate of sphincter-preservations and curative resections did not
increase. More local recurrences were seen in the group random-
ized to a longer time interval (9 vs. 1%, not statistically significant),
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Table 1 | Relevance of the time interval from short-course RT to surgery with level of evidence.
Interval (from the last 5Gy fraction) Surgical morbidity Tumor regression Oncologic outcome
2–4 days (reference) Known (limited) Ib 0 I Known (50–70% reduction in LR) I
5–~15 days Increased III Detectable III Likely the same III
20+daysa Known (limited) II Yes, pCR 10–15% I Not yet known, the Stockholm III trial may give information IV
Late toxicity from short-course RT will likely be the same irrespective of the time interval.
aNo information about surgical morbidity or tumor regression is available if the interval is only 3–6 weeks or longer.
bLevel of scientific evidence according to GRADE (Roman numbers, I–IV where I = high quality, II = moderate quality, III = low quality, and IV = very low quality) (60).
but fewer systemic relapses. More down-staging was also seen in
the Stockholm III study in an evaluation of the first 400 patients
randomized to short-course RT with delayed surgery compared
to immediate surgery (pCR in 13 vs. 2%, p< 0.001) (58). Similar
findings were reported in a retrospective evaluation of 67 Dutch
patients (59).
To summarize (Table 1), 5Gyx5 results in down-staging that
is apparent in large patient series already after 11 days after the
first radiation fraction. It becomes clinically and radiologically
apparent in individual patients after 3–4 weeks, permitting radical
surgery in patients with initially non-resectable tumors. A pCR is
seen in 10–15% in tumors belonging to the intermediate/bad and
locally advanced/ugly groups. Whether a delay to surgery changes
the oncologic outcome will not be known until results from the
Stockholm III trial are available (in 2015). Delaying surgery for
4 weeks or more does not result in more surgical morbidity than
if surgery is done immediately. Actually, it may be less. On the
other hand, several retrospective analyses have reported less toxi-
city if surgery is done, as originally intended, within the first few
days after the fifth radiation fraction. Thus, a longer than intended
interval should be avoided. If surgery can not be performed within
the first few days (not within the first week), it should be delayed
for at least 3–4 weeks, letting the acute radiation reaction subside.
TIME INTERVAL AFTER LONG-COURSE
CHEMORADIOTHERAPY TO SURGERY
PATHOLOGICAL COMPLETE REMISSION/TUMOR REGRESSION
Numerous studies have shown a correlation between the time
interval after RT to 45–50 Gy with concomitant fluoropyrimidine
(CRT) and the extent of tumor regression. A meta-analysis of 13
studies, including 3584 patients found that an interval longer than
the “conventionally” 6–8 weeks resulted in more pCRs (relative
risk 1.42, absolute increase from 14 to 20%) (35). In the largest
study, 1593 patients from 92 Dutch hospitals who underwent pre-
operative CRT between 2009 and 2011 (4) had the highest chance
of pCR if the CRT-surgery time interval was about 11 weeks (15–
16 weeks after start of CRT). Median interval was 9–10 weeks, likely
reflecting the common belief that a longer interval than used in
the randomized trials testing the value of pre-operative CRT (61–
64) is advantageous. The rate of pCR increased from 1 to 2% in
those operated within the first 5–6 weeks up to 14% if operated
after 11 weeks, with no apparent further increase beyond that time
(Figure 1).
Of several other retrospective analyses (3, 34, 65–67), not
included in the meta-analysis (35), only one (3) revealed a sig-
nificant association. Lymph-node retrieval was in one study lower
after neo-adjuvant therapy with an inverse correlation between
the yield and the time from (C)RT (68). This may influence
post-operative decision-making (69).
OTHER ENDPOINTS THAN TUMOR REGRESSION
Besides the established finding that tumor regression increases
with the duration of the interval, less is known about whether sur-
gical morbidity is decreased and oncologic outcomes improved
(sphincter- or organ-preservation, local recurrence rate, and sur-
vival). The meta-analysis (35) extracted information about these
outcomes from 6–8 of the 13 trials, including about 1300–2700
patients. No analyzed outcome differed according to time inter-
val. Thus, OS (RR= 0.85, 95% CI 0.5–1.43) and DFS (RR= 0.81,
95% CI 0.58–1.12) were not different. No difference was seen for
R0 resection and sphincter-preservation rates. Wound complica-
tions and anastomotic leak events were also similar (RR= 0.83,
p= 0.27).
More perineal wound complications [OR= 0.97 (95% CI 0.95–
0.99)] and anastomotic leakage [OR= 0.97 (95% CI 0.94–1.00)]
were seen with shorter interval (by 1 week) in a study that included
189 patients (34). Interval was not related to local recurrence,
metastasis, or death. This study could not detect any relation
between interval (median 10 weeks, range 1–30) and pathologi-
cal outcome. No other study has reported any detectable influence
on the post-operative course.
With few exceptions, none of the other studies has reported
any influence on oncologic outcome. In a retrospective analysis
of 177 patients, more pCRs (31 vs. 17%) and fewer local recur-
rences (1 vs. 11%, p= 0.04) were seen with an interval above
8 weeks after CRT, but no difference in post-operative morbidity
was detected (70). Similarly, in a study including 132 patients, no
difference in morbidity was seen in patients operated after 7 weeks,
whereas more pCR/near pCR and improved DFS (p= 0.05) were
seen (71). In yet another analysis of 397 patients, delaying surgery
after CRT from 4–6 to 6–8 weeks did not increase tumor response,
sphincter-preservation rate or decrease morbidity or local recur-
rence rate (72). In the study, the anastomosis-related complication
rate was the same (4–6%) irrespective of the interval. In a study,
evaluating 33 patients treated with CRT including irinotecan, a
10- to 14-week interval did not influence post-operative morbid-
ity (or pCR-rates) compared to 4–8 weeks (73). In a study (65)
of about 160 patients treated with pre-operative CRT (47 Gy with
Xelox), an interval between 40 and 70 days was accompanied by
more alterations in the tumors, but unaccompanied by changes
indicating more favorable outcomes compared to an interval of
21–40 days. Post-operative complications were the same. In an
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analysis of 102 patients treated with pre-operative RT (45Gy x25)
alone, the recommendation was to operate as soon as possible,
unless sphincter-preservation could be possible (66). No difference
in the proportion of patients with an early tumor (pT0-2N0) or in
survival was seen whether the RT-surgery interval was shorter or
longer than 6 weeks. A longer time from diagnosis to surgery neg-
atively influenced metastasis-free survival (≥16 weeks, OR= 2.05,
p= 0.05). In another study of 88 patients, no differences were seen
in pCR-rate or down-staging whether the interval was shorter or
longer than 28 days (67). A pCR favorably influenced prognosis, as
reported by many others, but the study did not report whether the
CRT-surgery interval influenced prognosis or complication rates.
Two studies have used a fractionation schedule that differs
from all other studies. In the randomized Lyon R90-01 trial (74),
pre-operative RT (39 Gy in 13 fractions) was randomly followed
by surgery within 2 weeks or after 6–8 weeks. More clinical and
pathological down-staging was seen in the long-interval group.
Morbidity, local relapse, survival, or sphincter-preserving surgery
rates did not differ. In a retrospective evaluation of 250 patients
treated with hyperfractionated accelerated RT (41.6 Gy/26 frac-
tions×BID) with planned immediate surgery, patients who had
an interval of >5 days had better OS (69 vs. 47%, p= 0.002), DFS
(62 vs. 41%, p= 0.0003) but not local control (93 vs. 90%) (75).
The authors speculate if it is a matter of days?
To summarize (Table 2), long-course CRT to 45–50.4 Gy results
in down-staging that is more pronounced with longer CRT-
surgery interval, at least up to an interval of 10–11 weeks. This
is most easily appreciated as increased pCR-rates (35). Although
reported in one study (34), there is no evidence that a longer
interval within the time-span 4–12 weeks results in less morbid-
ity. Surgery within the first 3–4 weeks is not recommended due to
the acute radiation reaction. There is very limited experience with
intervals beyond 12 weeks, unless chemotherapy has been given
in the interval (see below). There is a fear that radiation-induced
fibrosis will make surgery more difficult, but this has not been
substantiated in any report. It is possible that chemotherapy in
the interval may delay or prevent the development of fibrosis. The
evidence that the CRT-surgery interval (4–12 weeks) influences
oncologic outcome is virtually lacking. Thus, there appears to be
no reason to prolong the interval from 4–6 to 6–8 weeks or more,
as suggested, in tumors upfront considered resectable to improve
local control rates or survival.
INCREASING THE DOSE AND/OR ADDING CHEMOTHERAPY
IN THE INTERVAL
In patients with non-resectable tumors or with resectable tumors
but unfit or unwilling to undergo surgery, the radiation dose has
since decades been increased to increase the possibilities to local
and total cure without surgery (2, 13). CRs were seen and a small
but definite proportion was cured (13). This has also recently
been reported from a Polish group; large fixed or locally recur-
rent tumors could be controlled with acceptable risks of late bowel
toxicity (77).
The randomized Lyon R96-02 trial revealed more sphincter-
preservation when three contact x-ray boosts (20–35 Gy) were
added to external-beam RT (39Gyx13) (78). Eighty-eight patients
were included. After 10 years, there was no difference in local
recurrence rates (about 10%) and OS (79).
In a study including 222 patients treated with external-beam
CRT and brachytherapy, a dose–response modeling revealed a
dose–response relationship, both for pCR [D50-92 (95% CI 19–
145)Gy] and for tumor regression [D50-72 (95% CI 65–94)Gy]
(80). Thus, comparably high doses are required to obtain a 50%
probability of a major response in locally advanced rectal cancers.
The time interval was not considered. In the randomized study by
the same group, a brachytherapy boost of 10 Gy in two fractions
after CRT to 50.4 Gy did however not increase pCR-rates (18% in
both arms, n= 248) (81). Major responses were increased (44 vs.
29%, p= 0.04).
Habr-Gama and co-workers in Brazil have since the early 1990s
explored the potential for organ-preservation, i.e., in a sense pro-
longing the interval to surgery indefinitely in patients with tumors
regressing completely (21). In 71 (28% of 265 patients) with cCR
after 12 months,only two local recurrences were seen. Their studies
will not directly throw more light on the most optimal (C)RT-
surgery interval, since their ambition has been to avoid surgery
whenever possible. They do however indirectly bring further light
on this issue. More recently, the radiation dose has increased
Table 2 | Relevance of the time interval from long-course CRT to surgery on different outcomes.
Outcome Effect of a longer compared
to a shorter interval
Reference
Systematic overview (35) Othera
pCR/regression Increased (OR 1.42) Yes (66)
Surgical morbidity, predominantly
wound healing, anastomotic leakage
Unchanged (RR=0.87) (slightly
decreased in one study)
Yes (34, 65, 70, 72, 76)
Overall survival Unchanged (RR=0.85) Yes (66, 76)
Disease-free survival Unchanged (RR=0.81) Yes (34, 66, 76)
Local recurrence Unchanged (66, 70, 72)
Sphincter-saving surgery Unchanged (65, 72)
Lymph-node retrieval Decreased (68)
aOnly references not included in the systematic overview (34) are listed.
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from traditionally 45–50 Gy to 54 Gy with chemotherapy (three
cycles of 5-FU/leucovorin after the CRT) given in the interval. A
high CR rate (65, 48% clinical, 17% pathological) was seen in 34
patients (27). Toxicity was acceptable. In a more recent publica-
tion (82), 47 (68%) patients out of 70 starting therapy had cCR
at 10 weeks. During the first year, eight (17%) patients recurred
locally. Of those with cCR at 12 months, four (10%) did so. The
authors believe that this dose-intensification/interval prolonga-
tion has resulted in improved results with half of the patients
never requiring surgery. Since patient selection may be as relevant
as therapy intensification, it is difficult to make firm conclusions.
Garcia-Aquilar (29) has similarly extended the interval from the
standard of 6–11 weeks, filling the extra gap with chemotherapy.
They reported only a small increase in the pCR-rates (18–25%).
Post-operative complications did not increase.
Repeated PET–CT examinations were used to explore the
optimal interval to evaluate tumor regression (83). Ninety-one
patients selected to treatment with CRT for potential organ-
preservation had FDG-PET at baseline, after 6 and 12 weeks. The
mean maximal SUV-uptake decreased from baseline to 6 weeks.
This decrease was not predictive for response, whereas a decrease
from 1 to 3 h at the 6 weeks investigation was (dual time-point
imaging). About half of the patients showed a further slight
decrease from 6 to 12 weeks, whereas half did not; rather, a slight
increase in SUVmax was seen (poor responders). A sustained cCR
was rarely seen in the group of poor responders. Although the rel-
evance of these changes in SUVmax uptake is not known, they may
indicate that for about half of the patients, tumor repopulation
starts after about 6 weeks.
Higher radiation doses have also in several other patient
series been associated with better tumor response, although often
confounded by more intensive chemotherapy (84–87). Thus, it
appears rationale to increase the dose to the tumor if it is impor-
tant to achieve more complete or major responses. This may be
relevant in peripheral parts of the tumor if the aim is to achieve an
R0 resection in initially non-resectable tumors with overgrowth
to adjacent structures (88), or centrally if the aim is sphincter- or
organ-preservation; otherwise not.
DISCUSSION
The knowledge about the relevance of the time interval from the
start (or the end) of pre-operative (C)RT is chiefly based upon ret-
rospective analyses of hospital-based series and a few population-
based and randomized studies. Since randomized studies directly
comparing two intervals without making any other intervention
are few in numbers, the level of scientific evidence is formally
poor but still based upon experiences collected during decades.
The three randomized studies (51, 57, 58, 74), all reported more
clinical and pathological down-staging with longer intervals to
surgery. Since this was also seen in a meta-analysis of several retro-
spective studies (35), and is logical, there is no doubt that a longer
time interval to surgery up to about 8–12 weeks after a radiation
dose equivalent to about 45–50 Gy in 4–5 weeks will result in more
tumor regression.
The randomized studies also showed that delaying surgery for
4–8 weeks is safe (51, 57, 58, 74). Actually, it is possible that sur-
gical morbidity after short-course RT is less if surgery is delayed
than if performed immediately, but this is confounded by patients
who were operated upon after a brief delay of only a few days,
revealing increased surgical morbidity (51). There may be a time-
period after short-course RT during which surgery should not
be performed (48, 52, 54, 55), even if there are indications that
knowledge about the increased morbidity seen when surgery is
performed between 10 and 20 days after the first 5 Gy fraction
can be handled (48, 56). Delaying surgery after long-course CRT
also appears safe. With the exception of one study that actually
showed less complications associated with longer delay (34), no
study reported more complications within the time-span of 4–
12 weeks. Even if patients have had surgery beyond 12 weeks, they
are so few that no conclusions can be made.
In patients responding with regression to RT, it is likely safe
from an oncologic perspective to delay surgery for at least sev-
eral weeks. Withers and Haustermans (89) also state that “there is
no tumor-related necessity for early post-radiation surgery.” The
standard doses used pre-operatively usually mean that the tumor
cells are not viable clonogens to metastasize, although caution
must be made concerning the great heterogeneity in response.
The increase in FDG-PET uptake between 6 and 12 weeks in half
of the predominantly early tumors treated for organ-preservation
in Brazil (83) may be an indication of repopulation. Thus con-
cerns must be expressed in tumors not responding well to the
radiation. There are no solid data telling that regrowth of the irra-
diated primary tumor or pathological lymph nodes has started
during a time interval of up to 10–12 weeks, but this has not
been extensively studied. In head- and neck-cancer, repopulation
starts soon after the radiation has stopped, with a proliferation
rate equal to 0.75 Gy/day (90). The knowledge about the corre-
sponding value for rectal cancer is limited (91), although it may
be longer than generally perceived. Rectal cancers are also hetero-
geneous in their proliferative activity and this influences radiation
sensitivity (92, 93).
Another concern, never expressed in any of the articles present-
ing results after different CRT-surgery intervals, is growth of dis-
seminated tumor cells not irradiated, although discussed by With-
ers and Haustermans (89). Adjuvant post-operative chemotherapy
has in the rectal cancer trials not shown the same clear benefit as
in the colon cancer trials (38, 94). When metastatic, colon, and
rectal cancers respond similarly to chemotherapy and primary
tumor site is not predictive of response or survival. There are
thus no tumor biological apparent reason to believe that there
should be a discrepancy in the adjuvant situation, although it
is known that on a group level, differences in molecular prop-
erties that could indicate chemotherapy resistance exist between
colon and rectal cancers (95). There are however many differences
between the trials that could explain this apparent discrepancy.
Since the number of trials and the number of patients in the
colon cancer trials are many more than in the rectal cancer tri-
als, it may be a power problem. The pre-operative RT/CRT could
not really influence the sensitivity of already disseminated cells,
but it could decrease tolerability to the treatment and thus result
in less gain. Further, in the colon cancer trials revealing signifi-
cant gains from adjuvant chemotherapy, patients have been treated
for at least 6 months, whereas in most adjuvant rectal cancer tri-
als, treatment has only lasted for 4 months. We have presently no
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knowledge about whether the efficacy of a 4-month treatment with
5-FU/leucovorin is as efficient as 6–8 months. This is neither true
for oxaliplatin-based combinations, although trials are presently
comparing 3 and 6 months treatment (96). Finally and potentially
most important, the adjuvant colon cancer trials showing signifi-
cant survival gains all required that the adjuvant treatment started
within 5–6 weeks after surgery. This has not been the case in the
rectal cancer trials.
Retrospective analyses have indicated that time to start of adju-
vant chemotherapy is relevant (97), but selection bias can not be
excluded. Some have indicated that prognosis is worse if the delay
is longer than 8 weeks, others if it is longer than 12 weeks. The
adjuvant therapy in colon cancer is proven, and valued by doctors
and patients, but it is still limited and it is quite possible that a
few weeks prolongation may mean proliferation of tumor cells so
that they are no longer possible to eradicate by the chemotherapy.
Then, a delay from about 5–6 to 8–10 weeks may be relevant. In
colon cancer patients, surgery is usually performed within a few
weeks and the adjuvant treatment can often start 5–6 weeks later,
i.e., a delay of at the most 2 months from diagnosis. In rectal can-
cer, planning and delivery of RT, particularly if long-course (C)RT,
waiting for surgery and for the post-operative recovery may mean
that the subclinical deposits do not receive any efficient systemic
chemotherapy until several months later. May be this is the clue
to the discrepancy in efficacy of adjuvant chemotherapy between
colon and rectal cancers. This calls for neo-adjuvant chemother-
apy, and trials are ongoing (98). This, however, further tells that
any prolongation of time from RT/CRT to surgery in a tumor
that is primarily resectable can only be deleterious. Statements
like “waiting for the highest degree of pathological response is
clinically relevant as it increases the chance of R0 resection” (4)
make no sense. The cited statement probably reflects the opinions
of many clinicians treating rectal cancer patients. In resectable
tumors, the chance of an R0 resection with proper surgery is not
increased even if the pathological response gets better, it should
be 100% anyhow. The cell kill is already done and any prolonga-
tion of the interval may only diminish the chance that adjuvant
chemotherapy will eradicate all cells. Tumors not responding well
to the (C)RT may also have started to repopulate in such a way
that it may metastasize, even if not believed (89).
Organ-preservation, or to prolong the interval indefinitely,
appears from the ongoing debate to be a new phenomenon, start-
ing with the Habr-Gama publications in 2004 (21, 99, 100). There
has for decades been a desire to avoid removal of the sphinc-
ters and to avoid major surgery in risk groups (1, 2), and RT has
been one tool to permit this. In my early carrier as an oncolo-
gist with interest in rectal cancer, we had in the late 1970s-early
1980s many elderly patients above 75–80 years whom it was too
risky to operate (today they are usually above 85–90 years) and
RT or CRT was used to locally control the disease. This was suc-
cessful in some, although most still suffered, sometimes severely
from the local tumor burden after a period of good relief (101).
The results clearly showed the heterogeneity in response among
rectal cancers. The radiation doses given then were as high as they
can be today even if the tumor could be not be precisely located
and delivery not so conformed as today. Thus, the expected toxi-
city today is less (77). A fluoropyrimidine was added as radiation
sensitizer already in those days when the wish was to reach as
high cell kill effect as possible, although the acute toxicity often
prevented its use throughout the treatment in elderly patients.
Despite more than 30 years of research, no more effective radiosen-
sitizer is available. Later randomized trials have shown that CRT
is more effective than RT (62–64), but the improvement is not
marked, although again valued by doctors and patients, and unfor-
tunately comes at a price with more acute and also late toxicity
(102, 103). The wish to obtain cCR has prompted many doc-
tors to prolong the interval to planned surgery even if there
is no or limited chance to avoid surgery or increase sphincter-
preservation. That prolongation is of no advantage for the patient,
and should be avoided since it can only be potentially delete-
rious. Until we know more from trials, it is better to keep the
(C)RT-surgery interval as short a possible, allowing the acute radi-
ation reaction not to start (short-course) or to subside (short- and
long-course).
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